Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China, has announced that it has received marketing approval from the Health Sciences Authority of Singapore for its enoxaparin sodium injection in four specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, and 0.8ml:80mg. The approval is valid for a period of one year, with the requirement for annual maintenance and renewal.
Enoxaparin sodium, a low molecular weight heparin, is recognized for its therapeutic efficacy in preventing venous thromboembolic diseases following orthopedic or general surgical procedures and in treating cardiovascular conditions such as deep vein thrombosis and unstable angina pectoris. The drug has been approved for marketing in over 40 countries and regions, including China, where its listed specifications have passed the generic quality consistency evaluation (GQCE), as well as in the US, European Union, and other jurisdictions.- Flcube.com
